Biodrugs

Papers
(The TQCC of Biodrugs is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond339
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis281
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis122
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy116
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making99
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor90
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome90
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery76
CAR-T Cells and the Kidney: Insights from the WHO Safety Database60
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials60
Acknowledgement to Referees60
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart45
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies44
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202240
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis39
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?36
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells36
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review35
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study34
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer33
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase33
Progress and Challenges in the Treatment of Fabry Disease33
Malaria Vaccines: Progress to Date33
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects32
Interleukin-23 Inhibitors in Inflammatory Bowel Disease32
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?32
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options30
Acknowledgement to Referees30
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series30
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review29
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment28
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?27
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience26
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight24
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?24
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy24
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network24
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa23
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine23
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study23
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis23
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects21
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics21
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig19
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu19
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study18
The Use of Biologics for Thyroid Eye Disease18
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression18
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis18
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab18
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Heal18
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials18
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection17
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database17
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review17
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria16
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies16
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases16
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs16
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine14
Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria14
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context13
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance13
Patients’ Perceptions of Biosimilars: A Systematic Review13
0.057748079299927